---
figid: PMC5226473__oncotarget-07-48854-g001
figlink: /pmc/articles/PMC5226473/figure/F1/
number: F1
caption: 'A non-canonical function of CDK4/6 that can be exploited for therapeutic
  benefit. Left: In a drug-resistant HER2-positive breast cancer cell, CDK4 phosphorylates
  RB and also interacts with TSC2. CDK4 activity enhances mTOR activity, leading to
  feedback suppression of upstream receptor tyrosine kinases (RTKs). Middle: When
  the cell is treated with a CDK4/6 inhibitor (red arrows), RB phosphorylation declines,
  suppressing cell proliferation. TSC2 phosphorylation also declines, reducing mTOR
  activity and relieving feedback inhibition on RTKs. Right: A CDK4/6 inhibitor- treated
  cell is thus primed to the effect of anti-HER2 therapy (e.g. lapatinib, trastuzumab).
  Combination therapy leads to more potent shutdown of mTOR activity and the combined
  mTOR/RB suppression enhances therapeutic effect. (Modified from Goel et al, Cancer
  Cell 2016 [])'
pmcid: PMC5226473
papertitle: 'CDK4/6 inhibition: the late harvest cycle begins.'
reftext: Shom Goel, et al. Oncotarget. 2016 Aug 2;7(31):48854-48856.
pmc_ranked_result_index: '16659'
pathway_score: 0.8973101
filename: oncotarget-07-48854-g001.jpg
figtitle: 'CDK4/6 inhibition: the late harvest cycle begins'
year: '2016'
organisms: Homo sapiens
ndex: c0f3ff1e-df13-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5226473__oncotarget-07-48854-g001.html
  '@type': Dataset
  description: 'A non-canonical function of CDK4/6 that can be exploited for therapeutic
    benefit. Left: In a drug-resistant HER2-positive breast cancer cell, CDK4 phosphorylates
    RB and also interacts with TSC2. CDK4 activity enhances mTOR activity, leading
    to feedback suppression of upstream receptor tyrosine kinases (RTKs). Middle:
    When the cell is treated with a CDK4/6 inhibitor (red arrows), RB phosphorylation
    declines, suppressing cell proliferation. TSC2 phosphorylation also declines,
    reducing mTOR activity and relieving feedback inhibition on RTKs. Right: A CDK4/6
    inhibitor- treated cell is thus primed to the effect of anti-HER2 therapy (e.g.
    lapatinib, trastuzumab). Combination therapy leads to more potent shutdown of
    mTOR activity and the combined mTOR/RB suppression enhances therapeutic effect.
    (Modified from Goel et al, Cancer Cell 2016 [])'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CDK6
  - ERBB2
  - AKT2
  - RHEB
  - AKT1
  - RPS6KB1
  - CDK4
  - EGFR
  - MTOR
  - RPS6KB2
  - ERBB3
  - AKT3
  - TSC2
genes:
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RHEB
  symbol: RHEB
  source: hgnc_symbol
  hgnc_symbol: RHEB
  entrez: '6009'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: p70-S6K
  symbol: P70S6K
  source: bioentities_symbol
  hgnc_symbol: RPS6KB1
  entrez: '6198'
- word: CDK4/6inhibition
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: -mTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: p70-S6K
  symbol: P70S6K
  source: bioentities_symbol
  hgnc_symbol: RPS6KB2
  entrez: '6199'
- word: HER3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: TSC2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
chemicals: []
diseases: []
figid_alias: PMC5226473__F1
redirect_from: /figures/PMC5226473__F1
figtype: Figure
---
